NCT00964821View on ClinicalTrials.gov

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

CompletedOBSERVATIONAL
Enrollment

459

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Chronic Myeloproliferative DisordersLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative NeoplasmsNonmalignant Neoplasm
Interventions
BIOLOGICAL

trivalent influenza vaccine

Patients or normal volunteers who will be vaccinated against the flu.

OTHER

Immunoenzyme technique

This test will determine the level of antibodies in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.

OTHER

Laboratory biomarker analysis

This test will count the number of T cells (the cells that kill the flu virus) in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.

Trial Locations (2)

91105

City of Hope Medical Group, Pasadena

91010-3000

City of Hope Comprehensive Cancer Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT00964821 - Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant | Biotech Hunter | Biotech Hunter